Aromatase inhibition to enhance assisted reproduction

An aromatase inhibitor, assisted reproductive technology, applied in aromatase inhibitors, improving women's follicle production, pharmaceutical preparations and related applications, can solve the problem of no dominant follicles

Inactive Publication Date: 2004-11-24
ARES TRADING SA
View PDF25 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0023] A PCOS pattern of follicles is observed at this time, with no dominant follicle (greater than or equal to 1.5 cm)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Aromatase inhibition to enhance assisted reproduction
  • Aromatase inhibition to enhance assisted reproduction
  • Aromatase inhibition to enhance assisted reproduction

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0402] This embodiment is a prospective controlled study, including 1 study group and 1 control group. The patients in the study group received letrozole (2.5 mg per day from the 3rd day to the 7th day of menstrual period) and FSH. Group received only FSH. The study group included 12 patients with unexplained infertility. The control group consisted of 55 patients with unexplained infertility. All patients received recombinant or highly purified FSH (50-150 IU daily from day 3 to day 7 until the day when hCG (10,000 IU) was given when 2 main follicles were larger than 2 cm). The FSH treatment regimen is based on the patient's clinical condition. Patients are not arbitrary. All patients underwent artificial insemination. There were no statistically significant differences between the study and control groups in age, weight, duration of infertility, number of prior fertilization cycles, semen volume, or type of FSH.

[0403] Table 1

[0404] NS means no meaning...

Embodiment 2

[0406] Fifteen patients were selected, who were given clomiphene citrate (CC) and did not ovulate (6 cycles), or ovulated but the endometrial thickness was less than 5 mm (24 cycles) and could not conceive. They were given letrozole orally at a dose of 2.5 to 5 mg daily from days 3 to 7 or days 5 to 9 of the menstrual period for at least 2 months after the cycle. Ovulation induction was given with 10,000 IU hCG. CC was given at 50-100 mg per dose on days 3-7 or 5-9.

[0407] Table 2

average

scope

median value

treatment solutions

Letrozole

CC

P value

Letrozole

CC

Letrozole

CC

Days of hCG administration

Day 14.5

Day 12.6

S

11th-18th

day

11th-16th

day

day 15

day 12

Give the last letrozole tablet to

Number of days between days when hCG was administered

6.7

4.4

S

2-9

2-7

7

...

Embodiment 3

[0411] table 3

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
thicknessaaaaaaaaaa
Login to view more

Abstract

The use of at least one aromatase inhibitor in the production of a medicament for improving the implantation and pregnancy rates for a female undergoing assisted reproduction treatment, which comprises one or more daily doses of an aromatase inhibitor (AI) for administration during assisted reproduction cycles or ovarian stimulation cycles, wherein the doses of AI are selected from amounts effective to reduce serum estradiol levels. Also disclosed are related pharmaceutical preparations and packages.

Description

technical field [0001] The present invention relates to a method of treatment for women undergoing assisted reproductive therapy and ovulation induction, the method comprising administering an aromatase inhibitor (AI). The invention also discloses pharmaceutical formulations and related uses. The present invention also describes a method for increasing follicle production in women, aiming at obtaining immature eggs and culturing the oocytes to mature in vitro. The method also includes giving aromatase inhibitors. Background of the invention [0002] Most assisted reproduction protocols use gonadotropins alone or in combination with other drugs to stimulate the growth and maturation of multiple oocytes. This is essential because of the need to recruit a large number of follicles to increase the chances of fertilization and to increase the number of embryos transferred to achieve an acceptable success rate. Recent advances in the understanding of superovulation, oocyte recov...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K31/00A61K31/4196A61K31/56A61K31/566A61K31/5685A61K38/24A61K45/06A61P5/24A61P5/32A61P15/00A61P15/08A61P43/00
CPCA61K45/06A61K31/00A61K38/24A61K31/5685A61K31/4196A61K31/56A61P15/00A61P15/08A61P43/00A61P5/24A61P5/32A61K2300/00
Inventor R·F·凯斯普M·F·M·米特瓦利
Owner ARES TRADING SA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap